26 June 2020 - EMA’s human medicines committee (CHMP) has recommended granting a marketing authorisation in the European Union for Kaftrio, the first triple combination therapy for the treatment of cystic fibrosis in patients aged 12 years and older who are homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator gene or heterozygous for F508del in the CFTR gene with a minimal function mutation. 

This treatment is expected to provide a new therapeutic option for many cystic fibrosis patients, including those with minimal function mutations where no treatment exists.

Read EMA press release